Case Report
JBRHD
Complement Amplifying Conditions and Atypical Hemolytic Syndrome should Eculizumab is the First Line Therapy?

Article(s) in October Issue
Journal of Blood Research & Hematologic Diseases received 44 citations as per Google Scholar report